Benign Prostate Diseases and Male Voiding Dysfunction
Conditions we treat within this category include:
- Benign prostatic hyperplasia (Enlarged prostate)
- Incomplete bladder emptying
- Urinary frequency
- Urinary urgency
One of the most common benign urologic conditions faced by men is benign prostatic hyperplasia, a condition in which the prostate is enlarged but is not cancerous. Over 80 percent of men will develop BPH, with 50 percent of men developing the condition by the age of 50. As men age, the prostate continues to grow. In men with BPH, the enlarged prostate puts pressure on the urethra and bladder. This weakens and irritates the bladder resulting in frequent urination, urgency to urinate, decreased urine flow and the feeling that the bladder is still full after urinating.
Other benign conditions include incontinence and lower urinary tract symptoms (LUTS), which include problems with voiding (release of urine) and obstruction (inability to release urine).
The Northwestern Department of Urology has a longstanding history of achieved breakthroughs in the understanding and treatment of common urological conditions such as BPH. In this podcast, Hayley Silver, MD, shares the latest advances in BPH treatment. Listen here
Inflammation is a significant finding in a variety prostate diseases including prostatitis, BPH, and prostate cancer. Our department studies microbial and autoimmune mediated inflammation and innate and adaptive immune mechanisms in prostate disease. Projects in the lab use a combination of in vitro studies, animal models and clinical specimen assays to improve the understanding of these conditions.
Real World Experience Of Holmium Laser Enucleation Of The Prostate With Patients On Anticoagulation Therapy. Agarwal DK, Large T, Stoughton C, Heiman J, Nottingham CU, Rivera ME, Krambeck AE.J Endourol. 2020 Dec 5.
The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review.Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumbikat P, Hayward SW. Asian J Urol. 2020 Jul; 7(3): 191–202.
Uropathogenic Escherichia coli-induced fibrosis, leading to lower urinary tract symptoms, is associated with type 2 cytokine signaling. Bell-Cohn A, Mazur DJ, Hall C, Schaeffer AJ, Thumbikat P. Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F682-F692.
Role of PAR2 in the Development of Lower Urinary Tract Dysfunction. Roman K, Murphy SF, Done JD, McKenna KE, Schaeffer AJ, Thumbikat P. J Urol. 2016 Aug;196(2):588-98.
Our urologists offer a multidisciplinary approach in the diagnosis and treatment of BPH and LUTS, including behavioral, medical, procedural and surgical options. Treatments are tailored to each patient based on their symptoms, lifestyle and preferences.